Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Hombach

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|February 7, 2003
Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel diseaseCarsten Schmidt, Thomas Marth, Bianca M Wittig, et al.
Cancer Research|June 18, 2003
Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancerSilke Reinartz, Andreas Hombach, Siegmund Köhler, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 22, 2021
IL12 integrated into the CAR exodomain converts CD8<sup>+</sup> T cells to poly-functional NK-like cells with superior killing of antigen-loss tumorsAndreas Hombach, Markus Barden, Lisa Hannappel, et al.
International Journal of Cancer|April 20, 2004
Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cellsClaudia Heuser, Stefan Guhlke, Alexander Matthies, et al.
Rejuvenation Research|July 3, 2008
CD7(-) T cells are late memory cells generated from CD7(+) T cellsGunter Rappl, David Schrama, Andreas Hombach, et al.
Leukemia & Lymphoma|May 24, 2013
Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killingKerstin Brinkmann, Andreas Hombach, Jens Michael Seeger, et al.
Leukemia & Lymphoma|May 29, 2003
Cellular immunotherapy after autologous hematopoietic stem cell transplantation: experimental strategies and clinical experiencesHinrich Abken, Andreas Hombach, Günter Reinhard, et al.
Blood|July 27, 2006
XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attackHamid Kashkar, Jens-Michael Seeger, Andreas Hombach, et al.
Blood|May 18, 2007
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin diseaseBarbara Savoldo, Cliona M Rooney, Antonio Di Stasi, et al.
Plos One|March 18, 2021
Anti-CD19 CAR T cells potently redirected to kill solid tumor cellsChristine Ambrose, Lihe Su, Lan Wu, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|February 7, 2003
Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel diseaseCarsten Schmidt, Thomas Marth, Bianca M Wittig, et al.
Cancer Research|June 18, 2003
Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancerSilke Reinartz, Andreas Hombach, Siegmund Köhler, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 22, 2021
IL12 integrated into the CAR exodomain converts CD8<sup>+</sup> T cells to poly-functional NK-like cells with superior killing of antigen-loss tumorsAndreas Hombach, Markus Barden, Lisa Hannappel, et al.
International Journal of Cancer|April 20, 2004
Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cellsClaudia Heuser, Stefan Guhlke, Alexander Matthies, et al.
Rejuvenation Research|July 3, 2008
CD7(-) T cells are late memory cells generated from CD7(+) T cellsGunter Rappl, David Schrama, Andreas Hombach, et al.
Leukemia & Lymphoma|May 24, 2013
Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killingKerstin Brinkmann, Andreas Hombach, Jens Michael Seeger, et al.
Leukemia & Lymphoma|May 29, 2003
Cellular immunotherapy after autologous hematopoietic stem cell transplantation: experimental strategies and clinical experiencesHinrich Abken, Andreas Hombach, Günter Reinhard, et al.
Blood|July 27, 2006
XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attackHamid Kashkar, Jens-Michael Seeger, Andreas Hombach, et al.
Blood|May 18, 2007
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin diseaseBarbara Savoldo, Cliona M Rooney, Antonio Di Stasi, et al.
Plos One|March 18, 2021
Anti-CD19 CAR T cells potently redirected to kill solid tumor cellsChristine Ambrose, Lihe Su, Lan Wu, et al.
Pageof 3